The Science of Stickiness: How a New Patent Could Reshape Nasal Medicine

RAANANA, ISRAEL – June 17, 2026 – In the complex world of biotechnology, progress often hinges on mastering the mundane. Today, Israeli biotech firm Polyrizon Ltd. (Nasdaq: PLRZ) announced a development that centers on a deceptively simple concept: making things stick. The company confirmed the U.S. publication of patent application No. US 2024/0358741 A1, a move that formally unveils the architecture of its “Trap & Target” (T&T) platform and strengthens its position in the rapidly expanding field of nasal drug delivery.

While a patent publication is a routine step in a long journey, this one provides a glimpse into a technology that aims to solve a fundamental challenge in medicine. For decades, the nasal route has been a tantalizing but frustrating alternative to pills and injections. It offers a direct, rapid path into the bloodstream, bypassing the digestive system and liver. The problem? The nose is remarkably efficient at cleaning itself. Most of what is sprayed inside is cleared away in minutes, long before a drug can be fully absorbed. Polyrizon’s technology is a sophisticated attempt to outsmart this natural defense system, using a proprietary hydrogel to create a kind of biological velcro, holding therapies in place long enough to do their job.

A More Effective Biological Velcro

At the heart of the T&T platform is a concept called mucoadhesion—the ability of a material to adhere to a mucosal surface. The patent application describes a biocompatible gel designed to be sprayed into the nose, where it forms a thin, durable, and sticky film. This isn't just any gel; it's a carefully engineered formulation combining sulfated polysaccharides with hydrophilic polymers, crosslinked with divalent ions.

In simpler terms, Polyrizon has created a smart material. When sprayed, it has the right viscosity to be delivered as a fine mist, but upon contact with the nasal mucosa, it transforms. It creates a stable matrix that can “trap” an active pharmaceutical ingredient (API) and hold it against the highly vascular tissue inside the nose. This extended residence time is the key. By preventing the body's natural clearance mechanisms from washing the drug away, the platform aims to significantly increase the amount of drug absorbed into the system.

This could be a game-changer for a wide array of treatments. The patent outlines potential applications for anti-inflammatory drugs, vaccines, and complex biologics—large-molecule drugs that are typically difficult to administer outside of a clinical setting. By improving bioavailability, the technology could allow for lower doses, potentially reducing side effects and making treatments more efficient.

The Multi-Billion Dollar Nasal Frontier

Polyrizon’s innovation doesn't exist in a vacuum. It enters a market that is quickly becoming one of the most dynamic sectors in pharmaceuticals. The global nasal drug delivery market, valued at over $7 billion in 2026, is projected by some analysts to more than double to $15 billion by 2036. This growth is fueled by a convergence of factors: patient demand for non-invasive treatments, the need for rapid-acting drugs in emergency situations (like opioid overdoses), and the pursuit of new pathways to treat neurological disorders.

This last area, known as nose-to-brain delivery, is a particularly compelling frontier. The nasal cavity offers a unique backdoor to the central nervous system, potentially allowing drugs to bypass the formidable blood-brain barrier. This has made nasal sprays a hotbed of research for treating conditions like Alzheimer's, Parkinson's, and migraines.

However, the industry's challenges remain significant. Formulating drugs that are soluble, stable, and readily absorbed is a constant struggle. Polyrizon is one of many companies, from pharmaceutical giants to specialized startups, working to solve this puzzle. The publication of its patent application is a strategic move to carve out its intellectual territory in this competitive landscape.

Polyrizon's Two-Track Strategy

For a development-stage company with a market capitalization of just over $20 million, a clear strategy is essential. Polyrizon is pursuing a two-pronged approach. Its more advanced platform, “Capture and Contain” (C&C), is designed as a preventative barrier—a “biological mask” to block viruses and allergens. The lead candidate from this platform is already advancing toward U.S. clinical trials.

The Trap & Target platform is a different and potentially more lucrative play. While C&C is a medical device, T&T is a drug delivery system, designed to be paired with valuable pharmaceutical compounds. The patent publication, which follows a similar filing in Europe, is a crucial step in building a defensible IP portfolio that can attract the partners needed to bring such a platform to market.

Polyrizon is already laying the groundwork. The company has forged collaborations to explore the use of its technology for non-opioid pain treatment with SciSparc, for exosome-based therapies targeting spinal cord injuries with NurExone, and for psychoactive drug administration with an unnamed psychedelics company. These partnerships not only validate the platform’s versatility but also represent a capital-efficient R&D model, leveraging the expertise of others to explore new applications.

The Long Road from Patent to Patient

It is crucial to view today's announcement with a grounded perspective. A patent application publication is not a granted patent, and a clever technology is not an approved drug. Polyrizon, which is not yet profitable and relies on capital markets for funding—having raised approximately $3.5 million in April 2026 and $17 million in 2025—faces a long and arduous path forward.

The T&T platform is still in the pre-clinical phase. Ahead lie years of rigorous testing to prove its safety and efficacy, followed by the complex and expensive process of human clinical trials. The company will also have to navigate the FDA's regulatory framework for drug-device combination products, which scrutinizes both the formulation and the spray mechanism.

Success will depend on solid clinical data, continued access to funding, and the ability to secure a major pharmaceutical partner for commercialization. Yet, the publication of this patent application is a critical milestone. It solidifies an innovative concept in a public forum, providing the foundation upon which future development, partnerships, and ultimately, a new generation of medical treatments could be built.